Assessing the impact of canagliflozin therapy on HbA1c, body weight, and systolic blood pressure in patients with type 2 diabetes


eMediNexus    17 January 2018

A study published in the Current Medical Research and Opinion journal assessed the achievement of composite endpoints of glycated hemoglobin (HbA1c), body weight (BW), and systolic blood pressure (BP) targets with canagliflozin in comparison with placebo in patients with type 2 diabetes mellitus. The results demonstrated clinically significant reductions in these parameters in those who were administered canagliflozin. At week 26, greater number of patients achieved the composite endpoint of HbA1c reduction ≥ 0.5%, BW reduction ≥ 3%, and systolic BP reduction ≥ 4 mmHg with canagliflozin than with placebo. Moreover, a larger proportion of patients attained the composite endpoint of HbA1c < 7%, BW reduction ≥ 3%, and BP < 130/80 mmHg with canagliflozin in contrast to those who were given placebo. Canagliflozin displayed a favorable tolerability profile.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.